2nd How to Diagnose and Treat
Virtual Conference – #ESHAL2020
June 30 – July 2, 2020
Chairs : Hervé Dombret, Arnold Ganser, Jorge Sierra, Wendy Stock
Virtual Conference – #ESHAL2020
June 30 – July 2, 2020
Chairs : Hervé Dombret, Arnold Ganser, Jorge Sierra, Wendy Stock
Conference Chair Persons
Medizinische Hochschule Hannover
Professor Dr. Arnold Ganser has been Head of the Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation at Hannover Medical School since 1995. He is an expert in the acute leukemias and the myelodysplastic syndromes with special emphasis on molecular genetics and individualized treatment strategies, including the ethical and economic impact of individualized therapy. His scientific work has been published in more than 750 original publications in the New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia, Cancer Cell, Nature Medicine, Nature Immunology, Nature Genetics, Annals of Hematology, and others. He is co-chair of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG), the ASH International Consortium on Acute Leukemia, and member of the executive committee of the German Leukemia Network. He is editor-in-chief of the “Annals of Hematology” since 2003. He also serves as International Councillor on the Executive Committee of the American Society of Hematology.
Hospital de la Santa Creu i Sant Pau
Since 1997, Dr Jorge Sierra has been the Director of the Hematology Department and Hematopoietic Transplantation Program at the Hospital de la Santa Creu I Sant Pau, Barcelona.
Dr Sierra graduated in medicine and surgery in 1979 and from 1980 to 1983 he trained in hematology at the Hospital Clínic of Barcelona (Profs. Ciril Rozman and Emili Montserrat), receiving his PhD from the University of Barcelona. Between 1995 and 1996, he was a visiting scientist at the Unrelated Donor Transplant Program, Fred Hutchinson Cancer Research Center, Seattle. He was Vice-Dean of the Faculty of Medicine of the Autonomous University of Barcelona where he became a full Professor of Medicine in 2006. His research interests include the clinical impact of molecular alterations in acute myeloid leukemia and the novel modalities of AML treatment and hematopoietic transplantation.
He is President of the Spanish CETLAM cooperative group for study of acute myeloid leukemia, and a board member of the PETHEMA Foundation. Dr Sierra has been President of the Spanish Society of Hematology (term 2016-2019) and also a board member of the José Carreras International Leukemia Foundation. Until June 2015 Dr. Sierra was member of the Executive Committee of the European Hematology Association (EHA). For four years he also served as co-chair of the Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and was a member of the advisory board. Other past appointments were Director of Research of the Blood and Tissue Bank of Catalonia and Coordinator of the Health and Life Sciences Division of the Catalan Agency of Research. Dr Sierra has published more than 400 peer-reviewed articles in journals such as New England Journal of Medicine, JAMA, Lancet, Nature Reviews in Clinical Oncology, Blood, Leukemia, and the Journal of Clinical Oncology among others.
The University of Chicago Medicine
Dr. Stock is a tenured Professor of Medicine at the University of Chicago Medicine.. At a national level, she serves as co-chair of the Leukemia and Leukemia Clinical and Correlative Sciences Committees in the Alliance, a NCI-sponsored clinical trials cooperative group that leads national and international trials in leukemia clinical research, and served as the first chair of the NCI national clinical trials network (NCTN) Leukemia Steering committee, the committee which sets the agenda for all NCI sponsored large phase II and III trials in leukemia in the United States.
Dr. Stock is an expert in clinical and correlative laboratory research involving acute leukemias. Her focus has been to design biologically risk-adapted clinical trials for patients with acute leukemias, leading national trials for treatment of acute lymphoblastic leukemia (ALL) that have helped to change the standard of care for young adults with this disease. Dr. Stock has also established a young adult leukemia clinic at the University of Chicago which she runs jointly with her pediatric colleagues and which is committed to providing innovative research trials and clinical care to this patient population. Her work has focused on identifying new biological prognostic factors and molecular evaluation of minimal residual in specific subsets of leukemia that lead to novel clinical trial design..
Dr. Stock has published more than 200 peer-reviewed papers, reviews and book chapters and serves as Associate Editor of Blood Advances. She also served on the American Board of Internal Medicine hematology board that prepares the board certification examination in hematology. She has received a number of awards including the Gold DOC award for humanism in medicine, and is listed as a “Top Doctor” by both Chicago magazine, Newsweek magazine and US News and World Report. In 2014, she was awarded an endowed chair, the Anjuli Seth Nayak Chair for Leukemia Research, by the University of Chicago. In 2016, she received the Arthur Rubinstein Mentorship award from the University of Chicago department of Medicine. In 2017, she received the Distinguished Clinician award from the Biological Sciences Division of the University of Chicago. In 2018, Dr. Stock was awarded a director’s scientific leadership award by the National Cancer Institute and the Researcher of the Year award from the Leukemia and Lymphoma Society of America.
American University of Beirut
Ali Bazarbachi, MD, PhD is a Professor of Medicine (Hematology and Oncology), Professor of Anatomy, Cell Biology and Physiological Sciences, Associate Dean for basic research, and Director of the bone marrow transplantation program at the American University of Beirut-Medical Center. He received his MD and PhD degrees, residency and fellowship training at the University of Paris VII in France. Dr. Ali Bazarbachi’s research focuses on developing oncogene-targeted therapies for human leukemia and lymphoma as well as post-transplant pharmacological interventions. He has co-authored more than 270 articles in leading scientific journals including The New England Journal of Medicine, Science, Journal of Experimental Medicine, The Lancet Oncology, Journal of Clinical Oncology, Nature Communication, Blood, Leukemia, Cell Death and Differentiation, Oncogene, and Cancer Research, and serves as a reviewer for many of these journals. He is the Chairman of the EMBMT Leukemia Working Party, Chairman of the NCCN Lymphoma Group for Middle East and North Africa, past President of the Lebanese Society of Hematology, and Associate Editor of Bone Marrow Transplantation.
Nicolas Boissel is Head of the Adolescent and Young Adults Unit, Department of Haematology, Saint-Louis Hospital, and Professor of Medicine at University Paris Diderot, Paris, France. After beginning his career as a research fellow at the Pasteur Institute and as an intern at Paris Municipal Hospitals, he did a PhD at the Department of Immunology at Saint-Louis Hospital in 2002 while completing his MD at the University of Paris VI. In 2005, he went on to become Assistant Professor at Saint-Louis hospital in the Acute Leukemia unit headed by Professor Hervé Dombret, before taking up his current position in 2010. He is engaged in therapeutics for patients with bone marrow disorders including acute leukaemia, lymphoma, and aplastic anaemia, with a specific focus of adolescent and young adult comprehensive care. He is the chairman of the French Oncohematology Group for Adolescents and Young Adults (GO-AJA). As member of French national cooperative groups for acute lymphoblastic leukaemia (GRAALL) and acute myeloid leukaemia (ALFA), he is involved in many trials designed to improve the outcome of acute leukaemia patients. His clinical research interests include the role of new oncogenic events and minimal-residual disease to stratify therapeutic approaches in acute leukaemia, and the development of immunotherapy in the field.
University of Dublin
Professor Bond is the UCD Brendan McGonnell Professor of Paediatric Molecular Haemato-oncology and Honorary Consultant Paediatric Haematologist at Children’s Health Ireland (CHI). He originally trained as a clinical and laboratory haematologist in Ireland. He completed a PhD in Molecular Haematology at Imperial College MRC Clinical Sciences Centre (now the London Institute of Medical Sciences) in London, where he also worked at UCL Institute of Child Health, Great Ormond Street Hospital and St. Mary’s Hospital. After a post-doctoral fellowship at Hôpital Necker-Enfants Malades in Paris, he returned to Ireland in 2018 to lead a new paediatric leukaemia research program between University College Dublin and the Irish National Children’s Cancer Service at CHI at Crumlin.
Thorsten Braun, MD, PhD
University Hospital Avicenne, Paris XIII University
Thorsten Braun, MD, Ph.D, is a professor of clinical hematology at the University Paris XIII, and his current clinical position is in the Department of Hematology at the Avicenne University Hospital, Bobigny.
Prof. Braun received his medical degrees at the Universities of Bonn (Germany), Freiburg (Germany) and Paris VI (France). He has received clinical training in hematology, internal medicine and oncology in Paris (France) and Mannheim (Germany) University Hospitals.
Prof. Braun`s research experience includes clinical research as principal investigator in hematologic diseases in several phase I-III trials and basic and translational research for Myelodysplastic Syndromes and Acute Leukemias.
Prof. Braun`s recent research interests relate to preclinical drug screening in Acute Leukemias and he is group leader of the Leukemia Translational Laboratory (Director Prof. Hervé Dombret) at the Institut de Recherche Saint Louis (University of Paris, France).
Prof. Braun is member of ASH and AACR and has more than 70 original publications in international peer reviewed journals, such as New England Journal of Medicine, Journal of Clinical Oncology, Blood and Leukemia.
University Hospital of Ulm
Lars Bullinger holds a full professorship for “Hematology and Oncology” and is the Medical Director of the Department of Hematology, Oncology and Tumorimmunology at the Virchow Campus of the Charité University Medicine in Berlin. His work is concentrating on translational research with a focus on the integrative analyses of “omics” and NGS data with the aim to further refine molecular tumor classification and to implement insights into innovative precision medicine approaches. In addition, Lars Bullinger’s work is also aiming to further advance innovative treatment concepts for hematological malignancies such as acute myeloid leukemia (AML) and he is coordinating the Charité Leukemia Program.
University Hospital Marburg
1990-1998 Medical training at the Charité, Humboldt University, Germany and the University of North Carolina, NC, USA
1999 MD Charité Berlin, Humboldt University
2007 Assistant Professor Hematology/Oncology, Philipps University Marburg
2008 Deputy of Director, Department of Hematology/Oncology/Immunology, Philipps University Marburg
2009 Head of Clinical Research Program „Drug Resistance in Cancer” KFO210
since 2013 Professor for Molecular Hematology ans Head of Cellular Therapy Program at the Carreras Leukemia Center Marburg
Sapienza University of Rome
I am currently an Assistant Professor in the Department of Cellular Biotechnologies and Hematology at the Sapienza University of Rome, Italy. After obtaining medical degree and residency in haematology in the Pediatric and Day Units at Sapienza University, I carried out a PhD at Sapienza University and at the Dana–Farber Cancer Institute in Boston, USA, focusing on genome-wide technologies, for the in depth analysis of lymphoid (both chronic, and mainly acute) malignancies.
My main clinical focus is on the management of adult acute lymphoblastic leukaemia, both in terms of translational research as well as development of clinical trials: PI/coordinator of most of the italian clinical trials on acute lymphoblastic leukemia.
PI of 3 academic grants.
Member of the GIMEMA (Gruppo Italiano Malattie Ematologiche dell’Adulto) and of the EWALL.
Author/co-author of more than 100 peer-reviewed manuscripts.
Author/co-author of 4 book chapters.
Emmanuelle Clappier is Associate Professor in Hematology of the University of Paris and in charge of the Molecular Diagnosis in the Hematology Laboratory at Saint-Louis Hospital, Paris.
After completing her PharmD and PhD degrees at Paris-Descartes and Paris-Diderot Universities in Malignant Hematology, she was a postdoctoral fellowship in the Laboratory of Hematopoietic and Leukemia Stem cells at CEA, Fontenay-aux-Roses, France. On the hospital side, she worked at the children hospital Robert Debré (2007-2014) on acute lymphoblastic leukemias (ALL), and then moved to Saint-Louis hospital in 2014 where she currently leads the molecular hematology lab for adult malignant blood diseases.
Dr Clappier’s main focus includes genetics, therapeutic targets and minimal residual disease in acute leukemia, especially B-cell precursor ALL (BCP-ALL). As the coordinator for biology of adult BCP-ALL in the French national cooperative group on adult ALL (GRAALL), she set up a referent molecular diagnosis laboratory and research group. She is a member of several scientific boards including the EuroMRD consortium and the French Society of Hematology.
Amsterdam, The Netherlands
VU University Medical Centre
Jorge E. Cortes
Georgia Cancer Center
Jorge E. Cortes
I am one of the worldwide experts in leukemia research, with a unique expertise in clinical and translational research in leukemia, particularly myeloid leukemias. I am currently the Director of the Georgia Cancer Center and hold the Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer. I recently retired form MD Anderson Cancer Center where I worked for 23 years, serving most recently as Deputy Department Chair and Chair of the Chronic and Acute Myeloid Leukemia sections in the Department of Leukemia. I also held the Jane and John Justin Distinguished Chair in Leukemia Research and was Deputy Division Head for the Cancer Network. I have been recognized with awards such as The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research by MD Anderson, The Dr. John J. Kenny Award and The Service to Mankind Award by The Leukemia & Lymphoma Society, the Leadership and Institutional Service Award from MDACC and the the John Goldman Award for lifetime contributions to CML research. I have authored more than 1000 manuscripts in peer-reviewed journals and I have been PI or Co-PI of more than 45 research studies. At MD Anderson I initiated and led the Leukemia Fellowship program, a unique program that I created in 2000, and have mentored more than 25 clinical fellows. I have worked on development and approval of new leukemia drugs such as bosutinib, ponatinib and omacetaxine for CML, glasdegib, CPX-351 and gilteritinib for AML, and others that have completed or are close to completing pivotal trials such as Quizartinib and crenolanib. I have served on the American Society of Hematology Scholar Award study section and I will now be serving in the Advisory Committee Member for the Women’s Reproductive Health Research (WRHR) grant. I have worked on extending care to underserved areas in countries with few resources, as director of the International CML Foundation, bringing diagnostic tools and education to patients and physicians with no access to these elements. I also have developed educational modules for patients in Latin America for CML, and worked with colleagues there to expand their diagnostic and monitoring capabilities and with continued medical education activities. In my new position at the Georgia Cancer Center, I am interested in bringing excellent care and research to underserved and underrepresented populations across Georgia. Read more.
University of Birmingham, Queen Elizabeth Hospital
Hôpital Robert Debré
He is director of the hematopoietic stem cell transplant program of Pediatric Hematology-Immunology department in Robert Debré academic hospital in Paris from 2006.
He is President of the Scientific Council from the French Society for Cancer and Leukemia in Children and Adolescents and member of the Scientific Board from the Pediatric Diseases Working Party of EBMT.
He participated to more than 175 papers indexed in PubMed.
MD Anderson Cancer Center
“Dr Naval Daver is an Associate Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center. He completed his medical school from Grant Medical College and Sir J J group of Hospitals, Mumbai followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine. He is a clinical investigator with a focus on molecular and immune therapies in AML and Myelofibrosis and is principal investigator on >25 ongoing institutional, national and international clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint and vaccine based approaches, as well as targeted and apoptotic therapies in AMLand is leading a number of these trials at MDACC. Dr Daver has published >200 peer-reviewed manuscripts and is on the editorial board of numerous hematology specific journals. He has also authored numerous abstracts at national and international conferences.”
The University of Texas at MD Anderson Cancer Center
My primary clinical focus is individualizing therapy and precision oncology in myeloid malignancies, particularly the incorporation of genomics into standard risk assessments and treatment algorithms, and the clinical evaluation of targeted therapeutics within molecularly-defined patient subgroups. I have over 7 years of experience in designing, overseeing, and executing successful clinical trials, from Phase 1 first-in-human dose finding studies to innovative Phase II investigator initiated trials to serving as the international lead of randomized Phase III studies.
My clinical research skills include expertise in trial design through the successful completion of a Master’s of Science in Clinical Epidemiology. Through this program I gained invaluable proficiency in epidemiology, biostatistics, trial design, and database management through the timely analysis of IDH mutations, serum 2-hydroxyglutarate (2HG) levels, and clinical outcome in AML patients treated on the ECOG 1900 trial. The hypothesis that IDH mutations contribute to AML pathogenesis through regulation of gene expression via DNA hypermethylation, a process regulated by 2HG, and that 2HG measurement and quantification may become an important therapeutic and minimal residual disease marker, provided the essential groundwork for involvement in the developing evaluation of IDH mutations and IDH therapeutics in AML. This original research laid the groundwork for ongoing involvement in the development, design and execution of several practice-changing trials of novel targeted agents for AML.
I am fortunate to have served as the PI of multiple influential trials involving IDH and BCL2 inhibitors, with comprehensive translational and correlative analyses performed through established collaborations and taking advantage of our comprehensive departmental database, and processing and biospecimen bank. I am honored to have played an integral role in the development and subsequent FDA approval of three agents since 2017: the first-in-class IDH2 inhibitor enasidenib (AG221), the IDH1 inhibitor ivosidenib (AG120), as well as the BCL2 inhibitor venetoclax in combination with hypomethylating agents for newly diagnosed AML. Read more.
Washington University School of Medicine
Dr DiPersio has focused on developing novel targeted therapies for enhancing the outcomes of allogeneic stem cell transplant for patients with acute leukemia. Dr. DiPersio’s research focuses on fundamental and translational aspects of leukemia and stem cell biology. Over the past 30 years, Dr. DiPersio has established himself as a leader in the field through his leadership and membership on committees and organizations such as American Society of Hematology (ASH), multiple NIH, CIRM, LLS and CPRIT Study Sections, NIH Special Emphasis Panels and the NCI’s Board of Scientific Counselors. His >420 papers and consistent peer-reviewed funding demonstrate his scientific expertise. He is an elected member of ASCI and AAP, past president of the ASTCT (2018-19) and the recipient of the prestigious AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research in 2014, the ASH Mentor Award for Clinical Investigation in 2014 and a NCI R35 Outstanding Investigator Award in 2017.
Dr. DiPersio played a key role in the clinical development of plerixafor as a mobilizing agent for stem cell transplantation. His group was the first to show that disruption of the interaction of AML with bone marrow stromal cells using CXCR4 inhibitors sensitized AML cells to chemotherapy. His recent studies have focused on the development of novel methods of targeting the hematopoietic niche through the development of highly active small molecule inhibitors of CXCR4, VLA-4 and agonists of CXCR2 for both stem cell mobilization and chemosensitization. Dr. DiPersio was the first to implicate JAK1/2 signaling in GvHD via genetic and pharmacologic inhibition of INFR and IL-6R pathways. His preclinical work and early clinical trials led to the first drug ever approved by the FDA (ruxolitinib) for the treatment of steroid refractory acute GvHD. Recent studies by the DiPersio lab have uncovered the mechanisms by which JAK inhibitors alter T cell biology and have led to the identification of ‘best-in-class” JAK inhibitors for the prevention and treatment GvHD in man.
Dr. DiPersio played a critical supporting role in the sequencing of the first cancer genome and a leadership role in identifying genetic and epigenetic factors that contribute to relapse in AML. He was the first to show that rare subclones present at the time of diagnosis often are responsible for AML relapse. Recently, his group was also the first to show that epigenetic downregulation of HLA Class II antigens on AML blasts was associated with immune escape and relapse after allogeneic transplantation4. These observations have profound implications for how we diagnose, stratify and treat patients with AML. Finally, Dr DiPersio and his team have developed several exciting new bi-specific agents for the treatment of AML and lead the first trial of a bi-specfic DART (CD123 x CD3) in AML. Most recently, he and his team have utilized CRISPR/Cas9 gene-edited CART to CD7 and CD2 for the treatment of T cell hematologic malignancies. This represents the first viable off-the-shelf targeted CART therapy for T-ALL and T-NHL5. This has resulted in >20 patents and co-founding of two companies (Magenta Therapeutics, Cambridge MA and WUGEN, St Louis MO).
Pierre Fenaux trained at the University Hospital of Lille, France, where he became Professor in Hematology in 1993. Between 2002 and 2013 he founded and was head of the clinical hematology section at Hôpital Avicenne, Paris 13 University. He then moved to Hôpital St Louis, Paris 7 University to create a new clinical hematology section for myeloid disorders in the elderly, which he currently chairs. He is involved in clinical and laboratory research in the field of myelodysplastic syndromes (MDS) and acute myeloid leukemia (especially promyelocytic leukemia). He is a founding member and chairman of the French-speaking MDS group (Groupe Francophone des Myélodysplasies) and of the French APL group (GT-LAP). He is also a member of the board of directors of the MDS Foundation. He is the author of numerous scientific articles in peer-reviewed journals.
University of Birmingham
Sylvie Freeman is Professor of Immunohematology at Birmingham University, UK and director of its Clinical Immunophenotyping Service for the diagnosis and monitoring of hematological malignancies. Her training as a haematologist clinician scientist in Oxford with further clinical work at UCL, Bristol and Birmingham focussed her interests onto predicting treatment resistance in acute myeloid leukemia and myelodysplasia. She developed flow cytometric MRD detection for the UK NCRI acute myeloid leukemia trials and co-leads a combined immunophenotypic and molecular MRD monitoring strategy in these trials. Ongoing efforts to advance and optimise the detection of residual leukemic cells in trials and routine clinical practice have been strengthened by a network of collaborations with national and international leukemia colleagues that includes the European LeukemiaNet AML MRD Working Group and American Society of Hematology ICAL Laboratory committee.
Memorial Sloan Kettering Cancer Center
I have been involved in the field of hematopoietic cell transplantation (HCT) for more than 20 years. I am currently the Chief of the Adult Bone Marrow Transplant (BMT) Service at Memorial Sloan Kettering Cancer Center. As a mentor, I work to ensure that my mentees’ research projects and career development activities progress as planned. Additionally, I coordinate the mentoring efforts with all the members of the mentorship team, making certain that their research foundation is enriched through these efforts, and ultimately ensure that they are able to achieve their goal of becoming independent clinical investigators of the highest caliber. I meet with mentees on a weekly basis to provide input on research as well as grant proposals. During grant periods I continue to meet with my mentees regularly to directly address topics relevant to the proposed research plan, and advise them on interpretation and dissemination of findings, and provide guidance on career development topics.
Having had much experience in the leadership roles including the past president of the American Society of Blood and Marrow Transplant (ASBMT), I use every opportunity to connect my mentees with other leaders in the field and am committed to helping them successfully compete for larger grants and other opportunities. I have a recognized track record on mentorship, amongst my prior mentees many of whom are leading Bone Marrow Transplant programs and are independent clinical investigators such as Dr. Marcos de Lima, Dr. Hugo Fernandez, Dr. Avichai Shimoni, Dr. Simrit Parmar, amongst others. Another one of my mentees, Dr, Heather Landau, was promoted to Associate Professor and has become a leader in the field of light chain Amyloidosis and HCT and has already obtained significant foundation and industrial funding for her research. In addition to supporting mentees research and training, I am committed to their development. I advocate for their promotion opportunities, and ensure that they have the necessary resources, including training and personnel, to successfully complete all aspects of their projects and endeavors. Read more.
The University of Chicago Medicine
Dr. Godley developed her deep respect for science through her work in the Marchesi laboratories (Yale), Dr. Don Wiley (Harvard), and Dr. Harold Varmus (University of California, San Francisco and the National Institutes of Health). She completed her medical training at Northwestern University followed by Internal Medicine/Hematology-Oncology residency/fellowship at The University of Chicago. After postdoctoral research with Dr. Michelle Le Beau, Dr. Godley joined the faculty at The University of Chicago in 2003. As a physician-scientist with both research and clinical responsibilities, Dr. Godley seeks to understand disease on a molecular basis and is able to bring that perspective to the care of her patients. Her laboratory studies the molecular drivers of inherited hematopoietic malignancies and how the distribution of covalently modified cytosines in DNA influences cellular differentiation during hematopoiesis and tumorigenesis. Dr. Godley has established a robust clinical and translational pipeline for testing for germline predisposition mutations, and individuals who test negative for known risk alleles have contributed to research leading to the identification of two new predisposition syndromes. Dr. Godley serves as the Co-Chair of the American Society of Hematology Friday Scientific Workshop on Inherited Hematopoietic Malignancies as well as the ClinGen Myeloid Malignancy Variant Curation Expert Panel.
Centre Hospitalier de Versailles
Hôpital Universitaire Robert Debré
Dr Mechinaud gained her medical degree and her Doctor of Medicine (MD) degree at the University of Nantes, France. She completed paediatric and oncology haematology training in France at Nantes University Hospital, Necker Enfants Malades Hospital and Institut Gustave Roussy Paris. She also completed a research fellowship at the National Institute of Health (NIH) Bethesda (MD). Upon moving to Australia in 2009 she became a Fellow of the Royal Australasian College of Physicians (FRACP) in 2011.
Betweeen 1989 and 2009 Dr Mechinaud led the pediatric oncology unit in Nantes university hospital and was engaged in driving change in pediatric cancer care at the regional and national level She was member of the committee and chairman of the French society of pediatric oncology SFCE.
Between 2010 and 2019 Dr Mechinaud has been employed as pediatric oncology physician and head of BMT in the Children Cancer Centre (CCC) at the Royal Children’s Hospital (RCH), Melbourne. As of 2012, she held the position of director of the CCC. Dr Mechinaud has also been group leader of the Children’s Oncology Research Group with the Murdoch Childrens Research Institute. As director of the Children cancer centre she has driven some important change in the structure of paediatric cancer care to allow research driven care and comprehensive and family centred care. In this setting she engaged CCC in innovation in stem cell transplant and cell therapy .CCC was part of the ELIANA trial of CAR T cells and prepared CCC to become the first CAR T cell paediatric centre in Australia.
She moved back to Paris in 2019 and works in the Haematology unit in Hôpital Robert Debré. She is involved in transplant and CAR T cell program.
Hospital Universitari i Politècnic La Fe
Dr. Pau Montesinos, MD, PhD, is an attending physician at the University Hospital La Fe in Valencia, Spain, where he also co-ordinates the Research Unit of the Department of Hematology. He earned his medical degree in the Faculty of Medicine of Valencia, Spain, in 2000 and completed a hematology fellowship at the University Hospital La Fe in 2005. Dr. Montesinos’ main research interest is in the area of acute leukemia and stem-cell transplantation. Transplant coordinator in the hematology service from 2010 to 2016 and now leader of the acute leukemia program, principal investigator of more than 50 trials (form phase 1 to 3) in acute leukemias. Co-Chairman of the spanish PETHEMA AML and APL group, devoted to clinical trials design in acute leukemia, and carrying out an epidemiologic registry of iberian and latin-american AML/APL patients. Apart from the clinical experience, he is leading translational/biological projects of the PETHEMA cooperative group, setting-up a diagnostic biobank and laboratory centralization platform with harmonized procedures in Spain. Author of 170 pubmed indexed journal articles, he has published extensively on the treatment of leukemia in journals including Blood, NEJM, Journal of Clinical Oncology, Lancet Oncology, and Leukemia.
St. Jude Children’s Research Hospital
Charles Mullighan is a member of the Department of Pathology, Co-leader of the Hematologic Malignancies Program, Deputy Director of the Comprehensive Cancer Center and Director of the Biorepository at St Jude Children’s Research Hospital. He gained his medical degree from the University of Adelaide, Australia, undertook doctoral studies in immunogenetics in Oxford, and specialist training in hematology and hematopathology at the Institute of Medical and Veterinary Science in Adelaide. He joined St Jude as a postdoctoral fellow in 2004, and joined faculty in 2008.
Professor Mullighan’s research examines the genetic determinants of leukemogenesis and treatment response in acute lymphoblastic leukaemia (ALL) and high risk leukemias. His work has defined the genetic pathogenesis of multiple new subtypes of ALL, and several genetic alterations that have entered the clinic as new diagnostic and therapeutic targets. He is the recipient of numerous awards including an National Cancer Institute Outstanding Investigator Award, the Meyenburg Prize for Cancer Research and the American Society of Hematology Dameshek Prize.
Princess Margaret Cancer Centre
She then moved in Cambridge in the UK to complete her clinical and laboratory haematology training based in Addenbrookes Hospital.
She obtained her FRCPath in 2004. On completion of training she started her leukemia fellowship in Princess Margaret Cancer Centre in Toronto.
She has been on staff as a clinician investigator since 2018.
Cardiff University School of Medicine
Oliver Ottmann is Professor and Head of Haematology at Cardiff University School of Medicine, UK. Before taking up his current position in 2015, he was Head of the Division of Molecular Therapeutics at the Goethe University in Frankfurt, Germany and Endowed Professor for Molecular Therapy Research of the Deutsche Jose Carreras Leukemia Foundation. He is the Co-Lead of the Cardiff Experimental Cancer Medicine Centre (ECMC), and a member of UK NCRI Clinical Trial Subgroups for AML, ALL and CML.
Professor Ottmann’s scientific interests focus on malignant hematology with a particular emphasis on clinical trials, translational research including biomarker identification and validation, minimal residual disease, pre-clinical drug development as well as mechanisms of leukaemogenesis and drug resistance. He is internationally recognized for his expertise in the therapy for BCR-ABL positive leukemias and as an early phase clinical trialist. Prof. Ottmann is a member of numerous international professional societies including the European Hematology Association (EHA), the European Working Group for Adult ALL (EWALL) and the American Society for Hematology (ASH). Professor Ottmann has authored or co-authored more than 280 articles in international peer-reviewed journals.
Perelman Center for Advanced Medicine
Universitat Autonoma de Barcelona
Professor Josep-Maria Ribera is a practising physician and researcher. He is the Director of the Stem Cell Transplantation Unit at the Hospital Universitari Germans Trias i Pujol (HUGTP) and Head of the Clinical Hematology Department for the Catalan Institute of Oncology (ICO) also at HUGTP. He joined the Josep Carreras Institute at its creation and participated in the process of creation of the Acute Lymphoblastic Leukemia research group.
Prof. Ribera has been Associate Professor of Medicine at the Autonomous University of Barcelona (UAB) since 2003. He teaches post-graduate courses at the UAB, University of Barcelona, the Universidad Internacional Menéndez y Pelayo, and the Escuela Nacional de Sanidad as well as carrying out other varied teaching duties.
His work and publications have made him well known internationally and he is a member of the Steering Committee for acute lymphoblastic leukemia of the European LeukemiaNet and the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL).
Prof Ribera’s research focuses on the study of new treatment approaches and prognostic factors in adult acute lymphoblastic leukemia and he collaborates closely with the Lymphoma research group in the study of therapy and prognosis in HIV-related lymphomas.
He has authored/co-authored more than 400 published clinical papers and 90 book chapters on Haematology, Oncology and Internal Medicine.
Rotterdam, The Netherlands
Erasmus Medical Centre
Dr. Anita Rijneveld started her medical career at the Amsterdam UMC in Amsterdam. There she also specialized as a hematologist. After this training she started working at Erasmus MC at the hematology department. Since then she has been head of the sickle cell center for adults with all kind of hereditary anemias. In addition, she conduct research in the laboratory and various clinical studies with new agents for acute lymphoblastic leukemia.
Weill Cornell Medicine
Universitätsklinikum TU Dresden
Christoph Röllig, MD, received his medical training at the Free and Humboldt Universities of Berlin, Germany, and graduated in 1998. From 1999 to 2006, he did his internship in internal medicine and hematology and oncology at the University Hospital in Dresden, and became a certified specialist for internal medicine in 2005 and for hematology and medical oncology in 2006. From 2006 to 2007, he did a master in Public Health and Health Services Research at the London School of Hygiene and Tropical Medicine in London, UK. From 2007 to 2008 he worked in evidence-based medicine and guideline development at the Agency for Quality in Medicine in Berlin, Germany. Since 2009, Christoph Röllig has been working as a consultant hematologist and head of the hematological Clinical Trial Unit at the University Hospital in Dresden. Since the same year, he has been leading the central study office of the Study Alliance Leukemia (SAL) study group as SAL secretary. In 2019, he was appointed Professor of Medicine of the University in Dresden, Germany. He has acted as principal investigator in several phase II and III trials evaluating treatment optimization in AML and published several papers on the topic of AML prognostication and treatment.
Nottingham University Hospital
He was Chair of the NCRI (formerly MRC) AML Working Group from 2011-2019 was a Co-Chief Investigator of the AML17 trial and is now the Chief Investigator of the ongoing NCRI AML18 and AML19 trials. He has published over 300 papers in the field of AML and allogeneic transplantation. His current work focuses on clinical trials particularly the integration of new agents into the treatment pathway and the use of MRD analysis for risk stratification in AML. In 2019 he was appointed Emeritus Professor of Haematology at Nottingham and in January 2020 he took up the post of Consultant in Haematology at Guy’s and St Thomas’ Hospital, London.
University of Pennsylvania School of Medicine
My career goal as an academic pediatric oncologist and translational physician-scientist is to develop precision medicine therapies for children with high-risk leukemias to improve clinical outcomes and minimize toxicities. I have prior training in the laboratories of Dr Crystal Mackall at the NCI (HHMI-NIH Research Scholars program), Dr Mignon Loh at UCSF (post-doctoral fellowship), and Drs Martin Carroll and Stephan Grupp at Penn and CHOP (mentored junior faculty). My research program focuses upon identification of targeted therapeutic strategies for childhood leukemias via (1) characterization of signal transduction networks and preclinical testing of kinase inhibitors in genetic subtypes of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), (2) preclinical testing of chimeric antigen receptor (CAR) T cell immunotherapies for high-risk AML and ALL, and (3) early-phase clinical testing of molecularly-targeted therapies for children with leukemia through the Children’s Oncology Group (COG) and other consortia. My laboratory has substantial expertise in kinase inhibitor investigation and CAR T cell immunotherapies in ALL and AML patient-derived xenograft models, as well as in phosphosignaling analyses and measurement of patients’ molecular responses to kinase inhibitors. Successful integration of our bench-based and clinical studies has led to several trials testing new therapies in children with high-risk leukemias. I have leadership roles in the COG ALL, Myeloid Diseases, and AML New Agents steering committees and am the COG Developmental Therapeutics Committee Vice Chair of Biology for Hematologic Malignancies. I chair the COG AALL1521 clinical trial (ruxolitinib/chemotherapy for children with Ph-like ALL), co-lead immunotherapy trials for children with relapsed AML (PEPN1812 flotetuzumab phase 1, CD33CART phase 1), and am PI of the CHOP Center for Childhood for Cancer Research leukemia biorepository. My deep and complementary expertise in leukemia kinase signaling, leukemia immunotherapy, and early-phase clinical investigation of targeted therapies will continue to facilitate successful development of new precision medicine treatment paradigms for children with high-risk leukemias. Read more.
Children’s Hospital of Philadelphia
Prof. David T. Teachey is a laboratory based physician scientist with a strong track record of both basic science and clinical research. His research focuses on investigating disease biology and novel therapeutics in acute lymphoblastic leukemia (ALL), using preclinical models and translating those studies into the clinic. In collaboration with the Children’s Oncology Group (COG), he uses primary patient samples for this research.
His lab has developed xenografts from over 400 unique patients, focusing on patients with high-risk genetics or immunophenotypes, such as Philadelphia chromosome-like B-ALL or early T cell precursor T-ALL. He has also developed xenografts from diagnosis-relapse pairs, allowing study of clonal evolution, the biology of relapse, or the investigation of therapeutics targeted at lesions acquired (or selected) at relapse that alter epigenetics or signaling pathways. This work has led to a number of nationwide COG-initiated clinical trials in patients with ALL. For many of these trials, the correlative biology is performed in his laboratory. He holds a number of leadership roles in ALL in the COG: He is a member of the COG ALL disease steering committee, the leader of the T-ALL clinical trial and biology task force, and Vice Chair for ALL Biology.